Systemic lupus erythematosus is a chronic autoimmune disease of complex clinical
presentation and etiology and is likely influenced by numerous genetic and environmental …

Systemic lupus erythematosus (SLE) is characterized by multiple autoantibodies and
complement activation. Recent studies have suggested that anti-nuclear antibody (ANA) …

Objectives: To study associations between antinuclear antibodies (ANA) and
signs/symptoms in patients with systemic lupus erythematosus (SLE). Methods: A …

Objective Replacement of standard immunofluorescence methods with bead‐based assays
for antinuclear antibody (ANA) testing is a new clinical option. The aim of this study was to …

Systemic lupus erythematosus (SLE) is a heterogeneous disease with respect to disease
manifestations, disease progression and treatment response. Therefore, strategies to …

Objective. Associations between autoantibodies and clinical features have been described
in systemic lupus erythematosus (SLE). Herein, we aimed to define autoantibody clusters …

Presently we recognize at least 12 different autoantibodies that involve ribonucleoproteins
as antigens in patients with SLE and other rheumatic diseases. Such autoantibodies have a …

Objective A high number of antinuclear antibody specificities can be detected in systemic
lupus erythematosus (SLE). Some of them are related to a distinct clinical subset of disease …

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple
organ inflammatory damage and wide spectrum of autoantibodies. The autoantibodies …

Systemic lupus erythematosus (SLE) characterizes by a variety of clinical manifestations and
the presence of a wide profile of autoantibodies. This clinical and serological heterogeneity …